专利检索 ap:("Centaurus Biopharma Co., Ltd.") AND inv:"WANG, Shulong" 第 1 页

1.

发明授权
PHENYLUREA DERIVATIVES AS ISOCITRATE DEHYDROGENASE 2 INHIBITORS FOR TREATING CANCER 有权

公开(公告)号：EP3330263B1

公开(公告)日：2020-11-18

申请号：EP16829888.3

申请日：2016-07-29

申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.

发明人： WANG, Shulong , ZHAO, Na , LIU, Xijie , HU, Yuandong , ZHANG, Hui , LUO, Hong , PENG, Yong , XIAO, Dengming , HAN, Yongxin , ZHANG, Xiquan , TIAN, Xin

IPC分类号： C07D333/24 , C07D409/12 , C07D213/56 , C07D231/12 , C07D409/10 , C07D333/20 , C07C275/42 , A61K31/17 , A61K31/38 , A61K31/381 , A61K31/397 , A61K31/415 , A61K31/4418 , A61K31/4436 , A61K31/4535 , A61P35/02

2.

发明公开
SUBSTITUTED PYRROLOPYRIMIDINE CDK INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF 审中-公开

公开(公告)号：EP3434676A1

公开(公告)日：2019-01-30

申请号：EP17769492.4

申请日：2017-03-27

申请人： Chai Tai Tianqing Pharmaceutical Group Co., Ltd. , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.

发明人： WANG, Shulong , CHEN, Kuncheng , LIU, Xijie , HU, Yuandong , LIU, Bo , PENG, Yong , LUO, Hong , HAN, Yongxin , WANG, Shanchun , LIU, Mei , XU, Hongjiang

IPC分类号： C07D487/04 , A61K31/519 , A61P35/00 , A61P35/02

摘要： The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect.

3.

发明公开
1, 3, 5-TRIAZINE DERIVATIVE AND METHOD OF USING SAME 审中-公开

公开(公告)号：EP3330258A1

公开(公告)日：2018-06-06

申请号：EP16829878.4

申请日：2016-07-29

申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.

发明人： ZHAO, Na , WANG, Shulong , LIU, Xijie , HU, Yuandong , ZHANG, Hui , LUO, Hong , PENG, Yong , HAN, Yongxin , ZHANG, Xiquan , XU, Hongjiang

IPC分类号： C07D251/18 , C07D251/26 , A61K31/53 , A61P35/00

CPC分类号： A61K31/53 , C07D251/18 , C07D251/26

摘要： Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers.

4.

发明公开
ANTITUMOR COMPOUND TARGETING IDH2 MUTATION AND METHOD OF USE THEREOF 审中-公开

公开(公告)号：EP3330263A1

公开(公告)日：2018-06-06

申请号：EP16829888.3

申请日：2016-07-29

申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.

发明人： WANG, Shulong , ZHAO, Na , LIU, Xijie , HU, Yuandong , ZHANG, Hui , LUO, Hong , PENG, Yong , XIAO, Dengming , HAN, Yongxin , ZHANG, Xiquan , TIAN, Xin

IPC分类号： C07D333/24 , C07D409/12 , C07D213/56 , C07C275/42 , C07D231/12 , C07D409/10 , C07D333/20 , A61P35/00 , A61P35/02

摘要： The present application relates to compounds represented by general formula (I), general formula (II) or general formula (III), and pharmaceutically acceptable salts or hydrates thereof, preparation methods thereof, and pharmaceutical compositions thereof. The compounds represented by general formula (I), general formula (II) or general formula (III) have inhibitory activities against isocitrate dehydrogenase 2 (IDH2), thereby being capable of treating IDH2 mutation-induced cancers.

5.

发明公开
2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS 审中-公开
标题翻译： 2,4-二氨基-6,7-二氢-5H-吡咯并[2,3-b]嘧啶衍生物ALS FAK / PYK2-HEMMER

公开(公告)号：EP2661437A1

公开(公告)日：2013-11-13

申请号：EP12732345.9

申请日：2012-01-07

申请人： Centaurus Biopharma Co., Ltd.

发明人： XIAO, Dengming , CHENG,Liang , LIU, Xijie , HU, Yuandong , XU, Xinhe , LIU, Zhihua , ZHANG, Lipeng , WU, Wei , WANG, Shulong , SHEN, Yu , LI, Gen , WANG, Yin , ZHAO, Sheng , LI, Chonglong , TANG, Jia , YU, Honghao

IPC分类号： C07D487/04 , A61K31/505 , A61P35/00 , A61P29/00 , A61P31/00 , A61P37/02

CPC分类号： C07D487/04 , A61K31/4523 , A61K31/519 , A61K31/5377 , A61K31/541 , C07D401/12 , C07D413/12 , C07D417/12 , C07D493/12

摘要： The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/ or Pyk2 mediated disorder or disease.